RORC and diabetes mellitus: It is noteworthy, that administration of the inverse RORγ agonists has proven pharmaceutical potential, as SR1001 significantly reduced diabetes incidence and insulitis in a type 1 diabetes model mice (Solt et al., 2015) and SR2211 has been reported to inhibit inflammation in a collagen-induced arthritis mouse model (Xue et al., 2016).